$TOVX News

Theriva Biologics Q1 EPS $(0.05), Inline

Why Is Theriva Stock Gaining Monday?

Theriva Biologics shares are trading higher after the company announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients.

Theriva Biologics shares are trading higher after the company announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients.

These stocks are moving in today's after hours session

Theriva Biologics shares are trading higher after the company announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients.

Theriva Biologics' VCN-01 Shows Immune-Mediated Activity And Improved Outcomes Across Subgroups In Phase 2b Pancreatic Cancer Trial At AACR 2026

Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics shares are trading higher after the company announced it received the FDA's general agreement for the Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma.

Theriva Biologics Announces It Receives FDA's General Agreement For Phase 3 Clinical Study Of VCN-01 To Treat Metastatic Pancreatic Adenocarcinoma

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Theriva Biologics Q4 EPS $(0.12) Beats $(0.50) Estimate

Thursday's session: most active stocks

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

Theriva Biologics Reported The Out-licensing Of SYN-020, To Rasayana Therapeutics, Inc., A Privately-held Company Targeting The Gut-organ Axis Biology To Discover And Deliver Transformative Gut-targeted Medicines For Patients With Chronic Inflammatory Diseases

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

Theriva Biologics To Present Data From VCN-01 Retinoblastoma Phase 1 Clinical Trial At APAO 2026

Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)